Company / Accounts Receivable
Arcturus Therapeutics Holdings Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$5.6M
FY2025
5-year range
$2.8M / $32.1M
FY2021-FY2025
Trend
+40.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 7 years, ranging from $2M in FY2020 to $32M in FY2023.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +21.2%.
Declined from $32M to $6M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 40.0% year-over-year.
- Peak accounts receivable was recorded in FY2023.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.6M | +40.0% |
| FY2024 | $4.0M | -87.6% |
| FY2023 | $32.1M | +1060.1% |
| FY2022 | $2.8M | -17.9% |
| FY2021 | $3.4M | +58.4% |
| FY2020 | $2.1M | -2.5% |
| FY2019 | $2.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026